We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+2.16%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$34.7B
AUM Growth
+$242M
(+0.7%)
Cap. Flow
-$120M
Cap. Flow
% of AUM
-0.35%
Top 10 Holdings %
Top 10 Hldgs %
14.95%
Holding
3,089
New
65
Increased
2,336
Reduced
597
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$47.6M |
| 2 |
Medtronic
MDT
|
+$41.4M |
| 3 |
SLB Ltd
SLB
|
+$25M |
| 4 |
American Airlines Group
AAL
|
+$19.2M |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$18.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$107M |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$68.5M |
| 3 |
Apple
AAPL
|
+$22.9M |
| 4 |
CFN
CAREFUSION CORPORATION
CFN
|
+$16.9M |
| 5 |
PETM
PETSMART INC
PETM
|
+$14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.74% |
| 2 | Financials | 14.67% |
| 3 | Healthcare | 14.62% |
| 4 | Industrials | 10.93% |
| 5 | Consumer Discretionary | 9.13% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Comcast
CMCSA
$87.1B
| $239M | 0.69% |
8,458,756
-145,784
| -2% | -$4.19M |
|
27
Oracle
ORCL
$339B
| $238M | 0.69% |
5,510,507
-103,818
| -2% | -$4.5M |
|
28
Amazon
AMZN
$2.45T
| $228M | 0.66% |
12,248,140
-140,120
| -1% | -$2.46M |
|
29
Cisco
CSCO
$456B
| $227M | 0.66% |
8,249,269
-78,681
| -0.9% | -$2.21M |
|
30
Walmart Inc
WMT
$902B
| $212M | 0.61% |
7,739,415
-71,160
| -0.9% | -$2.02M |
|
31
Visa
V
$705B
| $211M | 0.61% |
3,218,426
-41,194
| -1% | -$2.72M |
|
32
Amgen
AMGN
$212B
| $205M | 0.59% |
1,282,517
-8,065
| -0.6% | -$1.27M |
|
33
Qualcomm
QCOM
$169B
| $197M | 0.57% |
2,842,033
-73,748
| -3% | -$5.2M |
|
34
CVS Health
CVS
$138B
| $194M | 0.56% |
1,882,381
-55,625
| -3% | -$5.63M |
|
35
UnitedHealth
UNH
$387B
| $193M | 0.56% |
1,632,501
-19,916
| -1% | -$2.21M |
|
36
3M
MMM
$93B
| $191M | 0.55% |
1,385,793
-15,719
| -1% | -$2.17M |
|
|
37
Medtronic
MDT
$113B
| $178M | 0.51% |
2,279,006
+546,463
| +32% | +$41.4M |
|
38
Philip Morris
PM
$314B
| $171M | 0.49% |
2,274,893
-25,298
| -1% | -$2.05M |
|
|
AGN
39
DELISTED
Allergan plc
AGN
| $167M | 0.48% |
561,997
+167,076
| +42% | +$47.6M |
|
40
Biogen
BIIB
$32B
| $165M | 0.48% |
391,065
-6,863
| -2% | -$2.7M |
|
|
41
SLB Ltd
SLB
$74B
| $165M | 0.47% |
1,971,625
+300,084
| +18% | +$25M |
|
42
Union Pacific
UNP
$173B
| $163M | 0.47% |
1,507,921
-38,561
| -2% | -$4.53M |
|
43
Boeing
BA
$167B
| $162M | 0.47% |
1,081,142
-28,840
| -3% | -$4.2M |
|
44
McDonald's
MCD
$193B
| $162M | 0.47% |
1,658,802
-27,762
| -2% | -$2.63M |
|
45
Bristol-Myers Squibb
BMY
$129B
| $161M | 0.47% |
2,501,355
+2,046
| +0.1% | +$128K |
|
46
AbbVie
ABBV
$472B
| $157M | 0.45% |
2,675,831
-13,854
| -0.5% | -$837K |
|
|
CELG
47
DELISTED
Celgene Corp
CELG
| $150M | 0.43% |
1,304,633
-12,315
| -0.9% | -$1.47M |
|
48
RTX Corp
RTX
$291B
| $150M | 0.43% |
2,029,957
-14,460
| -0.7% | -$1.08M |
|
49
Mastercard
MA
$498B
| $146M | 0.42% |
1,684,986
+45,708
| +3% | +$3.97M |
|
50
Altria Group
MO
$126B
| $144M | 0.42% |
2,880,890
-38,225
| -1% | -$2.03M |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2015 Portfolio in Review
As of Q1 2015, RhumbLine Advisers held 3,089 positions worth $34.7B, up 0.7% from $34.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Trading was light in Q1 2015: portfolio turnover was 3.9%. RhumbLine Advisers opened 65 new positions and exited 54, leaving the 3,089-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q1 2015 buy was Qorvo: 254,331 shares worth $20.3M.
- RhumbLine Advisers added most to Allergan plc in Q1 2015, an estimated $47.6M increase.
- RhumbLine Advisers's biggest Q1 2015 reduction was Apple, cutting an estimated $22.9M.
- RhumbLine Advisers fully exited Allergan Inc in Q1 2015, selling an estimated $107M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $34.7B portfolio in Q1 2015.
- RhumbLine Advisers opened 65 new positions and closed 54 in Q1 2015.
- RhumbLine Advisers's portfolio value rose 0.7% quarter-over-quarter to $34.7B.
Based on RhumbLine Advisers's 13F filing for Q1 2015, filed 12 May 2015.